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erum Soluble
T2 as a Biochemical
arker of Acute Heart Failure
uture Areas of Research*
avier Dı´ez, MD, PHD
amplona, Spain
he investigation into biochemical markers is modifying the
pproach to the diagnosis and management of heart failure
HF). Over the last decade, natriuretic peptides (NPs) have
een shown to be particularly useful in confirming or
efuting the diagnosis of HF as well as stratifying long-term
isk profiles. Several novel cardiac, metabolic, and inflam-
atory biochemical markers have emerged in the field of
F, such as the soluble ST2 receptor (sST2).
The receptor ST2 is an interleukin (IL)-1 receptor (IL-1R)
amily member that has 2 primary isoforms regulated by
ifferent promoters. The transmembrane ST2 isoform (ST2L)
s a membrane-bound isoform with 3 extracellular immuno-
lobulin G domains, a single transmembrane domain, and an
ntracellular domain homologous to Toll-like receptors and
ther IL-1Rs. The sST2 isoform lacks the transmembrane and
ntracellular domains. Both ST2L and sST2 are transcription-
lly induced by mechanical strain in rat cardiomyocytes and
ardiac fibroblasts (1,2), as well as by IL-1, and phorbol ester
n cardiomyocytes (1).
See page 1458
Recently, IL-33 has been identified as a functional ligand
f ST2L. Sanada et al. (2) reported that IL-33 was
ranscriptionally induced by mechanical stretch, angiotensin II,
nd phorbol ester in cardiac myocytes and fibroblasts. IL-33
arkedly blocked angiotensin II- and phenylephrine-
nduced necrosis factor (NF)-B activation and hypertrophy
n cardiomyocytes. After pressure overload by transverse
ortic constriction, ST2/ mice had more left ventricular
ypertrophy, myocardial fibrosis, and chamber dilation, and
ecreased fractional shortening and survival compared with
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiovascular Sciences, Centre of Applied Medicalp
esearch, and Department of Cardiology and Cardiovascular Surgery, University
linic, University of Navarra, Pamplona, Spain.ild-type littermates (2). Furthermore, recombinant IL-33
reatment reduced hypertrophy and fibrosis and improved
urvival after transverse aortic constriction in wild-type
ice, but not in ST2/ littermates.
It has been found that treatment with sST2 antagonizes
he ability of IL-33 to block angiotensin II- and
henylephrine-induced hypertrophy in cardiomyocytes (2).
n addition, when cardiac fibroblasts are stimulated with
horbol ester, both sST2 and total IL-33 are induced, but
nbound IL-33 diminishes (2). Collectively, these data
uggest that sST2 functions in myocardium as a soluble
ecoy receptor and that the local ratio of IL-33 and sST2
ould regulate IL-33–mediated signaling.
Recent experimental and clinical studies have reported an
xcess of serum sST2 in different cardiac conditions. Tran-
ient increase of sST2 has been found after myocardial
nfarction in mice subjected to coronary artery ligation (1).
ncreased levels of sST2 have been reported in the circula-
ion of patients 1 day after acute myocardial infarction and
orrelated positively with creatine kinase and negatively
ith ejection fraction (1). In addition, it has been shown
hat high baseline levels of sST2 predicted congestive HF
nd mortality in patients with acute myocardial infarction at
0 days (3,4). Of interest, the combination of sST2 and
mino terminal B-type natriuretic peptide (NT-proBNP)
ignificantly improved risk stratification (4). Increased se-
um levels of sST2 have been reported in patients with acute
yspnea, whether due or not due to acute destabilized HF
5,6). Baseline serum sST2 level was also a strong and
ndependent predictor of mortality at 1 year in these
atients, its predictive ability being higher than the ability of
T-proBNP (5–7). Finally, abnormally high serum sST2
evels have been identified in patients with severe chronic
F (8). Change in sST2 over a 2-week period was a
ignificant predictor of mortality or transplantation in these
atients, independent of brain natriuretic peptide (BNP)
nd pro-atrial natriuretic peptide.
In this issue of the Journal, Rehman et al. (9) have analyzed
he patient-specific characteristics with effects on serum sST2
alues in a cohort of 346 patients with acute HF. In addition,
he authors have explored the association between serum sST2
evels and outcome in these patients. Serum sST2 levels
egregated with more severe New York Heart Association
unctional class symptoms, and presented an independent
nverse association with ejection fraction. In addition, serum
ST2 levels at presentation strongly predicted mortality from a
ew months from presentation to at least 1 year. In a multi-
ariate Cox model containing established clinical and bio-
hemical predictors, including BNP and NT-proBNP, sST2
emained a predictor of mortality. When both sST2 and NPs
ere elevated, the highest rates of death were observed in a
umulative hazard analysis.
Determination of disease severity and risk stratification in
atients with acute HF is particularly challenging for
hysicians with currently available tools. Thus, the study by
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October 28, 2008:1466–7 Serum Soluble ST2 as a Marker of Acute HFehman et al. (9) is timely for several reasons: 1) it shows
or the first time that serum sST2 levels in acutely decom-
ensated HF represent a biochemical marker of disease
everity; 2) it confirms that serum sST2 is a powerful and
ccurate biochemical marker for prediction of near-term
ortality in these patients; and 3) it adds prognostic
erformance to the standard biochemical marker, namely,
Ps. There are, however, several pathobiological and clin-
cal aspects not covered by the study by Rehman et al. (9)
hat will require further research.
First, as mentioned above, an excess of sST2 relative to
L-33 might be detrimental to the cardiomyocyte because of
ts ability to interfere with the cardioprotective effects of the
iomechanically activated fibroblast-cardiomyocyte IL-33/
T2L paracrine system. Then, understanding of the true
athophysiological meaning of serum sST2 levels in patients
ith acute HF requires the simultaneous assessment of the
irculating levels of IL-33.
Second, in addition to patients with acute HF and/or acute
yocardial infarction, patients with asthma (10) or autoim-
une diseases (11) may also have increased serum sST2 levels.
hus, it is necessary to prove that, in patients with acute HF,
erum sST2 reflects what is occurring at the cardiac level. That
roof will require performing invasive studies aimed to dem-
nstrate the following: 1) that the myocardial expression of
ST2 is associated with its serum level; 2) that there is a positive
radient from sST2 level measured in coronary sinus blood
oward its level measured in peripheral vein blood; and 3) that
erum sST2 is associated with alterations of left ventricular
orphology and/or function that develop when the myocar-
ium is submitted to biomechanical stress.
Third, no information is yet available on the impact of
reatment-induced longitudinal changes in sST2 levels over
ime on the clinical outcome and long-term prognosis of the
atient with acute HF. Two arguments support that an
nvestigation in this area is important. On the one hand, the
ossibility exists that, besides its potential detrimental
ffects on the myocardium, sST2 may be beneficial under an
mmunological point of view. In fact, sST2 has been shown
o inhibit the release of pro-inflammatory cytokines by
uman immune cells (12,13), and this property could be
dvantageous, taking into account that immune activation
nd increased production of pro-inflammatory cytokines
lay an important role in the progression of HF. On the
ther hand, among the criteria a biochemical marker should
ulfill to be clinically useful is that the knowledge of its
easured level should aid in medical decision making,
articularly in selection of an appropriate therapeutic inter-
ention. Because of the duality of actions of sST2 at the
ardiac and immune levels mentioned here, the role of this Kolecule in selection of therapy and monitoring of response
o therapy must be clarified.
In summary, the article by Rehman et al. (9) provides a
trong basis for additional research aimed to definitively
rove that circulating sST2 is a biochemical marker of the
iomechanical stress of the myocardium, and that its incor-
oration into the clinical management of patients with acute
F will improve their care.
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IMA, Av. Pı´o XII, 55, Pamplona, Navarra 31008, Spain.
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